参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌的临床效果观察  

Clinical Efficacy of Canzhepeiqi Soup Combined with FOLFOX4 Chemotherapy Regimens in Treatment of Advanced Liver Cancer

作　　者：陈红宙[1] 

机构地区：[1]浙江省奉化市中医院,浙江奉化315500

出　　处：《中国医学创新》2013年第23期37-38,共2页Medical Innovation of China

摘　　要：目的:探讨参赭培气汤联合FOLFOX4化疗治疗晚期肝癌的临床疗效及安全性。方法:选择本院近年来收治的晚期肝癌患者78例为研究对象,随机分为参赭培气汤组38例和对照组40例,对照组给予放化疗治疗,参赭培气汤组在放化疗基础上加用参赭培气汤治疗,对比分析两组患者的近期疗效及毒副反应发生情况。结果:参赭培气汤组化疗的近期总有效率显著高于对照组(P<0.05),且治疗期间毒副反应发生率明显低于对照组(P<0.05)。结论:参赭培气汤联合FOLFOX4化疗方案治疗晚期肝癌临床疗效满意,毒副反应少,安全、有效,值得临床推广应用。Objective： To explore the clinical efficacy and safety of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer.Method： To choose the advanced liver cancer patients in our hospital as the research object in recent years, and divided into Canzhepeiqi Soup group and control group randomly, to contrast and analyze the recent curative effect and adverse reaction.Result： The total effective rate of Canzhepeiqi Soup group was significantly higher than control group in the near future （ P〈0.05 ）, and the incidence rate of adverse reaction was significantly lower than control group （ P〈0.05 ） .Conclusion： Clinical efficacy of Canzhepeiqi Soup combined with FOLFOX4 chemotherapy regimens in treatment of advanced liver cancer is satisfied, and has less adverse reaction, it is safe and effective, is worthy of popularization and applicationl

关 键 词：参赭培气汤 肝癌 临床疗效 毒副反应 

分 类 号：R735.7[医药卫生—肿瘤]